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ABSTRACT
Introduction Children admitted to hospitals in resourcepoor settings remain at risk of both inpatient and postdischarge mortality. While known risk factors such as
young age and nutritional status can identify children at
risk, they do not provide clear mechanistic targets for
intervention. The Childhood Acute Illness and Nutrition
(CHAIN) cohort study aims to characterise the biomedical
and social risk factors for mortality in acutely ill children
in hospitals and after discharge to identify targeted
interventions to reduce mortality.
Methods and analysis The CHAIN network is currently
undertaking a multi-site, prospective, observational
cohort study, enrolling children aged 1 week to 2 years
at admission to hospitals at nine sites located in four
African and two South Asian countries. The CHAIN
Network supports the sites to provide care according
to national and international guidelines. Enrolment is
stratified by anthropometric status and children are
followed throughout hospitalisation and for 6 months after
discharge. Detailed clinical, demographic, anthropometric,
laboratory and social exposures are assessed. Scheduled
visits are conducted at 45, 90 and 180 days after
discharge. Blood, stool and rectal swabs are collected
at enrolment, hospital discharge and follow-up. The
primary outcome is inpatient or post-discharge death.
Secondary outcomes include readmission to hospital and
nutritional status after discharge. Cohort analysis will
identify modifiable risks, children with distinct phenotypes,
relationships between factors and mechanisms underlying
poor outcomes that may be targets for intervention.
A nested case–control study examining infectious,
immunological, metabolic, nutritional and other biological
factors will be undertaken.
Ethics and dissemination This study protocol was
reviewed and approved primarily by the Oxford Tropical
Research Ethics Committee, and the institutional review
boards of all partner sites. The study is being externally
monitored. Results will be published in open access peerreviewed scientific journals and presented to academic
and policy stakeholders.
Trial registration number NCT03208725.

Strengths and limitations of this study
►► The Childhood Acute Illness and Illness (CHAIN)

c ohort is a multi-country study that collects comprehensive data on clinical, laboratory, social, economic and behavioural exposures at multiple sites
in Africa and Asia.
►► Heterogeneity across sites (geography, rural/urban, varying HIV and malaria prevalence) increases
generalisability and may help identify context-
independent and dependent interventions.
►► Strict harmonisation of procedures, processes and
tools allows for comparability between sites.
►► This study is deliberately focused on hospitalised
children and is not designed to evaluate factors associated with prehospital care and timing of presentation to hospital.
►► Bias may be introduced by loss-to-follow-up after
hospital discharge if this occurs in more vulnerable children, or if participation in the study alters
outcomes.

INTRODUCTION
Despite impressive global reductions in child
mortality, more than five million children
under age of 5 die each year.1 These deaths
occur disproportionately in low-income and
middle-income countries (LMICs).2 Factors
underlying mortality risk are complex and
overlapping,
including
undernutrition,
acute and chronic co-morbidities, lack of
access to care, poor social support systems
and poverty.3 4 For many vulnerable children, these factors contribute to an unstable
health trajectory, with repeated episodes
of illness interspersed with short periods of
incomplete recovery (figure 1). In most areas
of the world, acutely ill children may not
access healthcare during episodes of illness.5
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Figure 1 A model of unstable health trajectory of a child
characterised by repeated illness and incomplete recovery.

Of those that do, studies have shown that children who
are hospitalised have a dramatically higher risk of death
both during hospitalisation and in the months following
discharge than their community peers, even when guidelines for treatment and clinical follow-up are followed.6–9
Thus, contact with the health system resulting in hospitalisation serves as an indicator of vulnerability and a
time point where children are readily accessible for intervention.10–13 While many interventions may be available
in hospitals, there are no clear interventions proven to
reduce post-discharge mortality. Undernutrition, HIV
infection at a young age and a history of repeated hospitalisation have emerged as important risk factors for
post-discharge death.3 9 14
Approximately half of all childhood mortality is associated with one or more forms of undernutrition, typically
identified using simple anthropometry.2 Mortality rates
among children with severe acute malnutrition (SAM)
are markedly elevated compared with the general population,15 but with effective treatment in the community
without infectious complications, case fatality may be as
low as 1%–2%.16 17 However, when children with SAM
are acutely ill, inpatient case fatality is often 15%–20%
in resource-poor countries, with many additional deaths
occurring after discharge, even among children who
appear to be recovering anthropometrically.18 Although
case fatality rates for children with moderate acute malnutrition (MAM) or stunting in hospital and after discharge
have not been widely reported, MAM and stunting are
more prevalent than SAM and may contribute to a greater
number of child deaths.2 19
Current guidelines for the clinical management of
acutely ill children with SAM, MAM or stunting are not
supported by strong evidence.20–23 In addition, while
measures of mid-upper arm circumference, weightfor-length and length-for-age can identify children as
malnourished, anthropometry does not identify the
mechanisms that link undernutrition to mortality nor
its underlying causes. In typical settings outside humanitarian emergencies, it is unclear to what extent malnutrition is driven by factors other than food intake,
including recurrent or chronic infection, intestinal or
2

systemic inflammation, malabsorption, disability, social
vulnerability, parental ill-health, maternal education and
agency, lack of financial resources, poor social support
and limited access to healthcare.24 Identifying markers of
vulnerability and the underlying mechanisms that drive
mortality may offer opportunity to target interventions
to improve outcomes in many low-resource settings. In
addition, understanding relationships between biological
and social risk factors may allow optimisation of intervention packages within specific groups to achieve the largest
mortality reductions.
The Childhood Acute Illness and Nutrition (CHAIN)
Network is a collaborative group of investigators working
across nine sites in four African and two South Asian
countries committed to improving child survival and
optimising growth and development outcomes in low-
resource settings. CHAIN is conducting a prospective
cohort study with the objective of determining the phenotypes of groups of children at highest risk, defining the
mechanisms underlying such risk and identifying modifiable targets for intervention.

METHODS
Objectives
The CHAIN Network is conducting a prospective cohort
study of approximately 4500 children aged 1 week to
2 years presenting to healthcare facilities with acute
illness deemed severe enough to require admission to
hospital at nine sites in six LMICs. Children are followed
throughout hospitalisation, discharge and for 6 months
post-discharge. The general objective of the study is to
characterise acutely ill children and their outcomes in
hospital and after discharge in order to identify modifiable pathways leading to death. Using these data, the
CHAIN network will prioritise interventions based on
deliverability and potential impact.
Specific objectives
1. To determine factors associated with (1) mortality in
hospital; (2) mortality after discharge; (3) readmission
to hospital and (4) poor nutritional recovery.
2. To determine differences in clinical, social, and pathophysiological (eg, metabolic, infectious and immune)
phenotypes between children of different nutritional
status at admission, discharge and follow-up.
3. To identify modifiable risk factors and potential interventions to reduce mortality among vulnerable
children.
The goal of the CHAIN Network is to identify interventions that can reduce child mortality beyond the current
recommendations for standard of care. Hence, prior to
participant enrolment, all study sites underwent a formal
assessment of their capacity and adherence to national
and international guidelines, including a survey of
human resources, materials, equipments, pharmaceutical
stock and laboratory capacity. All sites were provided with
support to ensure that the minimum standard of care
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achieved was in line with the national and international
care guidelines. All sites participated in an audit and feedback cycle of guideline adherence using the individual
patient data collected by the CHAIN.
Locations
Participating sites include rural and urban hospitals
in Bangladesh (icddr,b Dhaka Hospital and Matlab
Hospital), Burkina Faso (Banfora Regional Referral
Hospital), Kenya (Kilifi County Hospital, Mbagathi
Sub-County Hospital and Migori County Referral
Hospital), Malawi (Queen Elizabeth Central Hospital),
Pakistan (Civil Hospital, Karachi), and Uganda (Mulago
Hospital).
Patient and public involvement
The investigators who form the CHAIN Network leadership have extensive experience in the design and
conduct of trials focused on improving growth and
survival in children in Africa and Asia. The study was
designed specifically to reflect patient and public
priorities (child survival, reductions in hospitalisation
and improved growth). Working closely with Community
Advisory Boards at each site, as well as with a robust social
science team of researchers in Kenya and Bangladesh,
patient priorities, experience and preferences were carefully considered in the design and development of the
protocol and data collection instruments. The research
questions were also discussed with a number of internal
CHAIN Network and external experts in child survival at
a convention organised by the funder. Caregivers were
included in the Community Advisory Boards to provide
input and into the conduct of the study. At the conclusion of the study, results will be disseminated to participants via seminars and outreach events led by the site
Principle Investigators and the Community Advisory
Boards at each site.
Eligibility
Children aged 7 days to 23 months who are admitted to
hospital with an acute illness are eligible for enrolment.
Prior to October 2018, the lower age limit of enrolment
was 60 days and this was subsequently modified to allow
the inclusion of younger children.
Exclusion criteria include the following:
►► Unable to tolerate oral feeds in the 48 hours prior to
the onset of the current acute illness.

►►

►►

►►
►►
►►

►►
►►
►►
►►
►►

Underlying terminal illness that in the opinion of
the treating physician is likely to lead to death within
6 months.
Diagnosed with a condition that in the opinion of the
treating physician is likely to require surgery within
6 months.
Diagnosed with a chromosomal abnormality (syndromically or genetically diagnosed abnormality).
Primary reason for admission is trauma or surgery.
Requiring immediate resuscitation at admission
defined by ongoing cardiac or pulmonary arrest or
judged to be peri-arrest by the attending physician.
Previous enrolment in the study.
Sibling enrolled in the study.
Caregiver plans to move outside of the hospital catchment area within 6 months.
Caregiver is unwilling to attend study visits.
Lack of informed consent.

Screening
Each site has nominated a day on which weekly recruitment begins. The first eligible child in each enrolment group admitted to the hospital is identified and
approached for consent. This is repeated for every eligible
child admitted subsequently until weekly targets are met
for each enrolment stratum (see table 1). Although this
is a pseudo-random approach, all the procedures aim to
ensure that the study population adequately represents
the spectrum of nutritional states observed over the
recruitment period.
Potential participants are identified by clinical staff
and brought to the attention of the study team who verify
the eligibility. If eligible, the study is explained to caregivers in their primary language and written informed
consent to participate is sought. Caregivers who are unable
to write are asked to provide a witnessed thumbprint. If
consent is obtained, the child is enrolled and a unique
study number is allocated. If a child is deemed eligible
but is too sick for consent to be immediately sought, study
staff obtain verbal assent to collect both research and clinical samples at that time to avoid multiple needle insertions. If a caregiver who gave assent then chooses not to
provide full written consent, all research data and samples
are destroyed. Children classified as orphans or those
living in alternative care homes are eligible for enrolment
if an appropriate caregiver is present to provide consent
on the child’s behalf.

Table 1 Enrolment groups by age and nutritional status
Group

Target
Enrolment

Age >6 months

Age 1–6 months

Age <1 month

A
B
C

1800
1800
900

MUAC <11.5 cm or kwashiorkor
MUAC 11.5 to <12.5 cm
MUAC ≥12.5 cm

MUAC <11 cm or kwashiorkor
MUAC 11 to <12 cm
MUAC ≥12 cm

MUAC <9.5 cm or kwashiorkor
MUAC 9.5–10.4 cm
MUAC ≥10.5 cm

MUAC, mid-upper arm circumference.
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Enrolment
Enrolment is stratified by nutritional status, aiming at a
ratio of 2:2:1 (A: B: C) with group targets of 200 group A:
200 group B: 100 group C per site (table 1).
Mid-upper arm circumference (MUAC) was chosen
as the optimal measure for participant selection as it is
strongly associated with mortality, captures stunted children, varies less with dehydration than weight-based
indices and is easily measured in sick children.25 26
Procedures
All sites completed standardised training on variable
definitions, identification of clinical signs, measurement
of anthropometry, case report form (CRF) completion
and data entry prior to starting the study, and training
was repeated regularly. An independent study monitor
(WESTAT) was hired to conduct site assessments to
ensure harmonisation of study procedures across and
between sites, as well as to ensure compliance with regulatory standards. Results from WESTAT’s monitoring
visits are for internal purposes and will be made available to the principal investigators at each site, the study
funder, and the CHAIN Network leadership and coordination teams.
On satisfaction of the inclusion criteria and the completion of informed consent forms, a unique study identifier
(ID) is allocated. Baseline data, including demographic
and social information, a detailed clinical examination
and measurement of vital signs, including pulse oximetry,
are collected using the standardised CRF. Anthropometry is performed (head circumference, MUAC, weight
and length). At admission, biological samples, including
blood (up to 5 mL for research purposes), rectal swabs
and faecal samples are obtained. All children are offered
provider-initiated counselling and testing for HIV, and
a malaria rapid diagnostic test is done. Results of investigations performed for clinical care (complete blood
count [CBC], biochemistry, glucose or any other laboratory investigations collected) are abstracted and recorded
for study purposes. After treatment is initiated, data on
the child’s diet, social circumstances and, if the mother is
present, maternal mental health screening is undertaken.
Other data on maternal characteristics collected include
maternal MUAC, height, weight and demographic data.
Additional maternal variables are listed in the study’s
enrolment CRF, which is included as an online supplementary file.
During admission, hospitalised children are reviewed
daily and specific clinical features indicating illness
progression and treatments are recorded on a structured
daily CRF that is entered into the CHAIN database. In
the event of death in hospital, a standard mortality audit
questionnaire is completed by a designated member of
the study team.
At discharge, the same clinical assessment as at admission, including anthropometry, is conducted and blood
and faecal sampling are repeated.
4

Follow-up procedures
A home visit is conducted within 3 days of discharge. The
location of the household is recorded by Global Positioning System (GPS) and CRFs are used to capture information on the number of people living in the homestead,
access to clean water and improved sanitation, occupation, household assets, income and food security. Parents
and legal guardians are also interviewed about their
home and social situation, including challenges experienced when keeping their child and family healthy.
Children are followed-up again at 45, 90 and 180 days
after discharge at the study facilities, irrespective of scheduled or unscheduled outpatient visits for medical or nutritional care. A standardised questionnaire ascertaining
vital status, care-seeking and rehospitalisation history and
recent dietary intake (up to 7 days before contact with the
hospital) is collected and anthropometry, rectal swabs,
faecal specimens and blood samples are repeated at each
follow-up visit. Maternal mental health is screened again
at day 45.
Children judged to have significant illness at any
follow-up visit or at the home visit are referred to an
appropriate hospital, clinic or nutrition programme. The
study staff share any test result relevant to the patient’s
care with the clinical management team and families.
Parents and legal guardians are asked to bring their
child to the study clinic if they are concerned that the
child is unwell. Financial reimbursement for transport
and lost earnings at standard local rates is provided at
the clinic visit. Study participants who are readmitted to
study hospitals undergo the standard clinical assessment
delivered at enrolment. Participants who are admitted to
hospitals other than the study site hospital have medical
data abstracted onto standardised hospital readmission
forms. For deaths occurring outside the hospital, a verbal
autopsy to evaluate the cause of death is completed within
28 days of study staff becoming aware of a death, using
select questions from the WHO standard verbal autopsy
tool.27
Community participants
To establish community norms, 125 children at each site
living in the same community as hospitalised participants
are recruited as community participants based on the
following inclusion criteria: absence of known untreated
HIV or tuberculosis (TB); no hospital admission in the
14 days prior to contact with the study team and no previously participation in the study. The exclusion criteria
listed for hospitalised children also apply to community
participants.
At every site, one in four hospital participants has a
child enrolled from their community. The selection of
hospitalised participants is either every fourth participant,
or, in periods when enrolment in hospital was lower, for
example, during healthcare workers strikes, one community participant was retrospectively enrolled for every
second hospitalised participant. Community participants
are identified randomly from the hospitalised participants'
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home; a random number x (1–4) and direction (north,
south, east, west) are generated using an online tool
prior to visiting the home. Random number selection was
done using a web-based application, Random Number
Generator/Picker.28 Once at the home of the hospitalised
participant, the research team begin by visiting the xth
house in the generated direction and attempt to obtain
consent to enrol a child within the eligible age range
from that household. If not successful, they continue in
the same direction to the next xth house. This is repeated
until a child is enrolled. Children with severe illness
requiring hospital admission identified during community screening are referred for appropriate care.
When an eligible community participant is identified,
their caregiver is given information about the study
and invited to the study clinic for assessment. Following
confirmation of informed consent, a clinical examination
and anthropometry are completed and documented, and
blood and stool samples collected as in the hospitalised
children. Household and demographic questionnaires
are also administered. Children in this group requiring
non-urgent medical care receive basic treatment in the
study clinic and/or are referred to appropriate treatment centres after enrolment procedures are completed.
These children remain eligible for inclusion as community participants. Financial reimbursement for transport
and lost earnings at standard local rates is provided to
each caregiver at the clinic visit. No follow-up is done on
community participants.
Specimen collection
To ensure comparability, standard operating procedures
are followed at each site. Blood samples are collected
at enrolment, each day of hospitalisation, in the event
of clinical deterioration (defined by the onset of a new

Integrated Management of Childhood Illness danger
sign), at discharge, at all follow-up points and at any
hospital readmission. Blood is collected into a BD
Vacutainer Hemogard K2EDTA (spray dried) and a red
top with a clot activator (spray dried) at each time point
and three dried blood spots on Whatman filter paper
cards are prepared. At each time point, a CBC and clinical biochemistry, including sodium, potassium, calcium,
magnesium, urea, creatinine, albumin, bilirubin, alanine
aminotransferase, inorganic phosphate and alkaline phosphate are performed. Blood glucose, HIV testing (Alere
Determine or Uni-Gold HIV) and malaria rapid diagnostics tests (CareStart HRP2/pLDH) are also performed on
all children at enrolment and at additional time points, if
clinically indicated. Caregivers may refuse any sample
collection during the study without being excluded from
further follow-up. The schedule for blood collection is
detailed in table 2.
Fresh stool collected directly or from child diapers is
transferred into standardised stool collection pots by study
staff, aliquoted and stored at −80˚C. Advanced pathogen
detection using Taqman Array Card, sequencing, microbiome analysis, metabolomics, and markers of enteric
inflammation and dysfunction will be conducted on a
subset of stool samples in the CHAIN nested case–control
study.
Data management and confidentiality
Data recorded on standardised CRFs are de-identified
and entered in a secured central database and housed
on servers in Nairobi with secure offsite backup. Prior to
and after data entry, paper records are kept in a locked
room with locked filing cabinets at each site, with access
limited to investigators and study staff directly involved
in data collection and entry. For de-identification, only

Table 2 Schedule of blood samples and tests performed at each collection time point
Results used for
care

Complete blood count
Biochemistry

Admission Discharge Day 45

Day 90

Day 180 Readmission

X
X

X

X

X

X

X
X

Glucose

X

X

Blood gas+lactate*

X

X

Blood culture*

X

X

Malaria Rapid Diagnostic Test
(RDT)

X

X

HIV test

X

Processed or stored Dried blood spot
for research assays Serum+plasma for storage
only
Whole blood for storage

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

Functional immunology*

X

X

X

X

X

X

Peripheral Blood Mononuclear
Cell (PBMC) extraction*
Rectal swab and whole stool

X

X

X

X

X

X

X

X

X

X

X

X

*Done at a subset of sites with capacity, thus these are sub-studies.
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participant initials are recorded and any potential identifier such as date of birth and GPS location are stored
separately. Site principal investigators or their delegates
conduct regular internal quality assurance on completion, data transfer and storage of the Case Reporting
Forms (CRFs). A central data management system generates automated queries and reviews incoming data weekly.
Any missing or implausible data are queried and site
teams are given specific timeframe to resolve the raised
issues.
Analysis
Data from all Network sites will be combined as a single
cohort. Outcomes will be classified into one or more
of the following, the proportion of children with each
endpoint described with 95% CIs:
►► Death at any time during the period of observation
(primary endpoint).
►► Death in hospital.
►► Death after discharge.
►► Readmission to hospital within 180 days.
►► Nutritional status at 180 days.
►► Recovery as defined by survival without readmission or
development of SAM during 180 days after discharge.
Primary cohort analysis—mortality
The hazard of mortality during the study will be calculated
using multivariable survival models including (1) clinical signs and symptoms; (2) anthropometric markers of
wasting and stunting; (3) markers of organ function; (4)
birth history and prior health and (5) maternal, household and social factors. The stratified design by location
and nutritional category will be accounted for with multilevel fixed and random effects. Subgroup analyses will
be conducted for inpatient and post-discharge mortality,
including time-to-event survival analyses. Predictive algorithms will be built using methods such as classification
and regression trees, boosted regression trees and other
machine learning methods. Mechanistic pathways will be
interrogated using structured equation modelling, latent
class analysis and other methods.
Secondary cohort analysis
Secondary endpoints are rehospitalisation and the presence of SAM or MAM after 6 months. These will be
examined using generalised linear models accounting
for the competing risk of mortality. Growth trajectories
post-discharge will be compared with WHO standard
growth curves and modelled in relation to risk factors and
outcomes as panel data. Differences in mortality between
sites will be examined in relation to case-mix and underlying risk factors such as HIV and socioeconomic factors.
Nested case–control study
A nested case–control design will be utilised to investigate
mechanisms with advanced laboratory testing on stored
samples for efficiency. Cases will be defined as (1) children who died during follow-up and (2) children who
6

are readmitted to hospital. Controls will be selected from
children who survive to 6 months without readmission
(‘pure controls’), matched by site and nutritional strata
to reflect the study design.
Primary analyses will estimate the association between
the exposures of interest and the odds of poor outcomes
during follow-up. The exposures of interest in these analyses will include plasma and faecal markers of intestinal
dysfunction, systemic inflammation, systemic and enteric
pathogens, ‘maturity’ and diversity of the enteric microbiome, proteomic and metabolomic markers of energy
metabolism, and macronutrient and micronutrient status.
If mortality in the study is lower than expected (500
observed deaths), the primary case definition will be
expanded to include children who were enrolled but
were rehospitalised post-discharge. Samples from these
children may also be used in a sensitivity analysis to determine if associations with readmission with severe illness
(‘near-miss’) differ from those for mortality.
Sample size
Sample size calculations are based on expected events
(deaths) in the cohort. We anticipate based on prior
information from the sites that recruiting approximately
4500 children in the specified strata will result in 500
deaths in this population. The sample size estimation is
based on detecting differences in the proportion who die
post-discharge between moderately malnourished and
non-malnourished groups. Among non-malnourished
children, we assumed an inpatient case fatality proportion of 5.0%, a cumulative post-discharge mortality of
2.5% compared with 7.5% inpatient case fatality among
moderately malnourished children and allowing for 10%
loss to follow-up. For a two-sided hypothesis that Ha:
p2≠p1, with an α of 0.05, a power of 80% is attained for a
post-discharge case fatality of 4.8% or above.
For laboratory analyses on stored samples, a nested
case–control approach will compare cases (children who
die) and controls (children with good recovery) in a 1:2
ratio matched by site and nutritional strata. We expect
approximately 500 deaths will occur, with 1000 controls.
For a two-sided hypothesis that Ha: p2≠p1 at 80% power
and a significance level of 0.05, this allows for the determination of an OR of 1.8 for risk factors with a prevalence
of 5% among controls, and of 1.4 for risk factors with a
prevalence of 25%. Further analyses using a combined
secondary endpoint of death and/or rehospitalisation
will ensure adequate power to detect risk factors with
lower prevalence.
At each site, inclusion of 125 community participants
will permit the calculation of descriptive percentages
as integer values and estimates of community norms of
continuous variables.29 Across the whole study, 1025
community participants will be recruited. For a two-sided
hypothesis that Ha: p2≠p1, at 80% power and a significance level of 0.05 and assuming clustering by site, this
sample size allows for the determination of a prevalence
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ratio of 1.5 for risk factors with a prevalence of 5% among
community participants and a ratio of 1.25 for risk factors
with a prevalence of 25%.
Study timeline
The CHAIN Cohort Study began enrolling on 20th
November 2016 and participant recruitment and
follow-up is expected to occur through August 2019.
Potential challenges and limitations
The study is designed and powered to detect associations with mortality, the primary outcome. Prior data
from other studies conducted at the CHAIN sites suggest
that sufficient numbers of events will occur to achieve
adequate power. However, an interim analysis will be
conducted in 2019 to confirm that the cohort study is
adequately powered to detect the effects of covariates of
interest. In the event that mortality or enrolment rates
are not sufficient, we will include rehospitalisations as a
combined primary endpoint. This cohort study is being
conducted in low-resource environments where the risk
of civil, political or military disruption, and industrial
action affecting hospitals are significant. The inclusion of
multiple sites across a wide geographical range allows for
some sites to strategically increase enrolment if other sites
are unable to achieve planned targets.
Bias may occur if children lost to follow-up are not
representative of the study population; it is anticipated
that non-attenders may be more vulnerable. There is also
the risk of the Hawthorne effect where involvement in the
study alters outcomes.
Ethics and dissemination
Prior to project inception, the key stakeholders at each site
were engaged, including those from relevant Ministries of
Health, local academic institutions, hospitals hosting the
study and the community engaged in the research. Community Advisory Boards have been assembled at each site. Study
progress and results are shared with the key stakeholders as
well as disseminated through workshops and written materials. The CHAIN Network has both ethics and policy advisory boards to providence guidance on how to tailor research
activities and help disseminate key findings with enough
reach and power to influence high-level policy decisions.
Acknowledgements The CHAIN Network thanks all the patients and their families
for participating in this study. We acknowledge all leadership and staff at CHAIN
hospital sites, and especially the clinical staff for sharing their resources and time
to both care for CHAIN patients and collect pertinent data for the study.
Collaborators Berkley, JA (KEMRI/Wellcome Trust Research Programme, Kilifi,
Kenya; Center for Tropical Medicine and Global Health, University of Oxford, Oxford,
UK; Network PI). Walson, JL (Departments of Global Health, Medicine, Pediatrics
and Epidemiology, University of Washington, Seattle, Washington, USA; Network
PI). Diallo, AH (Department of Public Health, Faculty of Health Sciences, University
of Ouagadougou). Ki-Zerbo J, Ouagadougou, Burkina Faso; Department of Public
Health, Centre Muraz Research Institute, Ministry of Health, Bobo-Dioulasso,
Burkina Faso). Shahid, ASMSB (Nutrition and Clinical Services Division (NCSD),
International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b),
Dhaka, Bangladesh; Co-investigator). Gwela, A (KEMRI/Wellcome Trust Research
Programme, Kilifi, Kenya. Saleem, A (Department of Pediatrics and Child Health, The
Aga Khan University,Karachi 74800, Pakistan). Asad, A (Department of Pediatrics

and Child Health, The Aga Khan University, Karachi 74800, Pakistan). Tigoi, CC
(KEMRI/Wellcome Trust Research Programme, Kilifi,Kenya). Bourdon, C (Department
of Translational Medicine, The Hospital for Sick Children, Toronto, Ontario,
Canada). Lancioni, CL (Department of Pediatrics, Oregon Health and Science
University,Portland, Oregon, USA). Denno, DM (Department of Pediatrics,School of
Medicine, University of Washington, Seattle, Washington, USA; Department of Global
Health and Department of Health Services, School of Public Health, University of
Washington, Seattle, Washington, USA). Mangale, DI (Department of Global Health,
University of Washington, Seattle, Washington,USA). Mupere, E (Department of
Paediatrics and Child Health,College of Health Sciences, Makerere University,
Kampala, Uganda). Tickell, KD (Departments of Global Health and Epidemiology,
University of Washington, Seattle, Washington, USA). Mwangome, MK (KEMRI/
Wellcome Trust Research Programme, Kilifi, Kenya). Chisti, MJ (Nutrition and
Clinical Services Division (NCSD), International Centre for Diarrhoeal Disease
Research, Bangladesh (icddr,b), Dhaka,Bangladesh). Ngari, MM (KEMRI/Wellcome
Trust Research Programme, Kilifi, Kenya). Ngao, NM (KEMRI/Wellcome Trust
Research Programme, Kilifi, Kenya). Sukhtankar, P (KEMRI/Wellcome Trust Research
Programme, Kilifi, Kenya). Bandsma, RHJ (Centre for Global Child Health, The
Hospital for Sick Children,Toronto, Ontario, Canada; Division of Gastroenterology,
Hepatology and Nutrition, The Hospital for Sick Children, Toronto, Ontario,
Canada; Department of Nutritional Sciences, Faculty of Medicine, University of
Toronto, Toronto,Ontario, Canada; Department of Biomedical Sciences, College of
Medicine,University of Malawi, Blantyre, Malawi). Molyneux, S(KEMRI Centre for
Geographic Medicine Research — Coast and Wellcome Trust Research Programme,
Nairobi, Kenya; Centre for Tropical Medicine, University of Oxford, Oxford, UK).
Ahmed, T (Nutrition and Clinical Services Division (NCSD), International Centre for
Diarrhoeal Disease Research, Bangladesh (icddr,b), Dhaka, Bangladesh). Voskuijl,
W (Department of Paediatrics and Child Health,College of Medicine, University of
Malawi, Blantyre, Malawi; Department of Biomedical Sciences, College of Medicine,
University of Malawi, Blantyre,Malawi).
Contributors JB and JW led the proposal and protocol development with input
from all collaborators listed.
Funding This work was supported by the Bill and Melinda Gates Foundation, grant
number OPP1131320.
Competing interests None declared.
Patient consent for publication Not required.
Ethics approval This study protocol was reviewed and approved by the Oxford
Tropical Research Ethics Committee, UK; the Kenya Medical Research Institute,
Kenya; the University of Washington and Oregon Health and Science University,
USA; Makerere University School of Biomedical Sciences Research Ethics
Committee and The Uganda National Council for Science and Technology, Uganda;
Aga Khan University, Pakistan; the International Centre for Diarrheal Disease
Research, Bangladesh; The University of Malawi; The University of Ouagadougou
and Centre Muraz, Burkina Faso; the Hospital for Sick Children, Canada; and
University of Amsterdam, The Netherlands.
Provenance and peer review Not commissioned; externally peer reviewed.
Open access This is an open access article distributed in accordance with the
Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits
others to copy, redistribute, remix, transform and build upon this work for any
purpose, provided the original work is properly cited, a link to the licence is given,
and indication of whether changes were made. See: https://creativecommons.org/
licenses/by/4.0/.

REFERENCES

1. WHO. Children: reducing mortality World Health Organization:
WHO, 2018. Available: http://www.who.int/news-room/fact-sheets/
detail/children-reducing-mortality (updated 9/18/2018; cited 2018
10/24/2018).
2. Black RE, Victora CG, Walker SP, et al. Maternal and child
undernutrition and overweight in low-income and middle-income
countries. Lancet 2013;382:427–51.
3. Wiens MO, Pawluk S, Kissoon N, et al. Pediatric post-discharge
mortality in resource poor countries: a systematic review. PLoS One
2013;8:e66698.
4. Man WD, Weber M, Palmer A, et al. Nutritional status of children
admitted to hospital with different diseases and its relationship
to outcome in The Gambia, West Africa. Trop Med Int Health
1998;3:678–86.
5. CHERG. Underlying Causes of Child Death CHERG. http://cherg.org/
projects/underlying_causes.html (cited 10/24/2018).

The Childhood Acute Illness and Nutrition Network. BMJ Open 2019;9:e028454. doi:10.1136/bmjopen-2018-028454

7

Open access
6. Kerac M, Bunn J, Seal A, et al. Probiotics and prebiotics for
severe acute malnutrition (PRONUT study): a double-blind efficacy
randomised controlled trial in Malawi. Lancet 2009;374:136–44.
7. Maitland K, Berkley JA, Shebbe M, et al. Children with severe
malnutrition: can those at highest risk of death be identified with the
WHO protocol? PLoS Med 2006;3:e500.
8. Talbert A, Thuo N, Karisa J, et al. Diarrhoea complicating severe
acute malnutrition in Kenyan children: a prospective descriptive
study of risk factors and outcome. PLoS One 2012;7:e38321.
9. Fergusson P, Tomkins A. HIV prevalence and mortality among
children undergoing treatment for severe acute malnutrition in subSaharan Africa: a systematic review and meta-analysis. Trans R Soc
Trop Med Hyg 2009;103:541–8.
10. Kerac M, Bunn J, Chagaluka G, et al. Follow-up of post-discharge
growth and mortality after treatment for severe acute malnutrition
(FuSAM study): a prospective cohort study. PLoS One 2014;9:e96030.
11. Moïsi JC, Gatakaa H, Berkley JA, et al. Excess child mortality after
discharge from hospital in Kilifi, Kenya: a retrospective cohort
analysis. Bull World Health Organ 2011;89:725–32.
12. Chisti MJ, Graham SM, Duke T, et al. Post-discharge mortality in
children with severe malnutrition and pneumonia in Bangladesh.
PLoS One 2014;9:e107663.
13. Chang CY, Trehan I, Wang RJ, et al. Children successfully treated for
moderate acute malnutrition remain at risk for malnutrition and death
in the subsequent year after recovery. J Nutr 2013;143:215–20.
14. Heikens GT, Bunn J, Amadi B, et al. Case management of HIVinfected severely malnourished children: challenges in the area of
highest prevalence. Lancet 2008;371:1305–7.
15. Chen LC, Chowdhury A, Huffman SL. Anthropometric assessment of
energy-protein malnutrition and subsequent risk of mortality among
preschool aged children. Am J Clin Nutr 1980;33:1836–45.
16. Isanaka S, Langendorf C, Berthé F, et al. Routine amoxicillin for
uncomplicated severe acute malnutrition in children. N Engl J Med
Overseas Ed 2016;374:444–53.
17. Isanaka S, Langendorf C, Berthé F, et al. Routine Amoxicillin for
Uncomplicated Severe Acute Malnutrition in Children. N Engl J Med
2016;374:444–53.
18. Ngari MM, Mwalekwa L, Timbwa M, et al. Changes in susceptibility
to life-threatening infections after treatment for complicated severe
malnutrition in Kenya. Am J Clin Nutr 2018;107:626–34.

8

19. Bhutta ZA, Das JK, Rizvi A, et al. Evidence-based interventions for
improvement of maternal and child nutrition: what can be done and
at what cost? Lancet 2013;382:452–77.
20. WHO. Guideline: Updates on the management of severe acute
malnutrition in infants and children. WHO Guidelines Approved by the
Guidelines Review Committee. Geneva, 2013.
21. Picot J, Hartwell D, Harris P, et al. The effectiveness of interventions
to treat severe acute malnutrition in young children: a systematic
review. Health Technol Assess 2012;16:1–316.
22. WHO. Recommendations for Management of Common Childhood
Conditions: Evidence for Technical Update of Pocket Book
Recommendations: Newborn Conditions, Dysentery, Pneumonia,
Oxygen Use and Delivery, Common Causes of Fever, Severe
Acute Malnutrition and Supportive Care. Recommendations for
Management of Common Childhood Conditions: Evidence for
Technical Update of Pocket Book Recommendations: Newborn
Conditions, Dysentery, Pneumonia, Oxygen Use and Delivery,
Common Causes of Fever, Severe Acute Malnutrition and Supportive
Care. WHO Guidelines Approved by the Guidelines Review
Committee. Geneva, 2012.
23. Angood C, McGrath M, Mehta S, et al. Research priorities to improve
the management of acute malnutrition in infants aged less than six
months (MAMI). PLoS Med 2015;12:e1001812.
24. Bhutta ZA, Berkley JA, Bandsma RHJ, et al. Severe childhood
malnutrition. Nat Rev Dis Primers 2017;3:17067.
25. Berkley J, Mwangi I, Griffiths K, et al. Assessment of severe
malnutrition among hospitalized children in rural Kenya: comparison
of weight for height and mid upper arm circumference. JAMA
2005;294:591–7.
26. Myatt M, Khara T, Collins S. A review of methods to detect cases of
severely malnourished children in the community for their admission
into community-based therapeutic care programs. Food Nutr Bull
2006;27(3 Suppl):S7–S23.
27. WHO. Verbal autopsy standards: the 2012 WHO verbal autopsy
instrument. Geneva: WHO, 2012.
28. Hedges A. Random Number Generator / Picker. 2008 https://andrew.
hedges.name/e/random/ (cited 10/24/2018).
29. Horowitz GL, Altaie S, Boyd JC. Defining, establishing, and verifying
reference intervals in the clinical laboratory; approved guideline:
CLSI, 2010.

The Childhood Acute Illness and Nutrition Network. BMJ Open 2019;9:e028454. doi:10.1136/bmjopen-2018-028454

